Genome‑wide bioinformatics analysis reveals CTCFL is upregulated in high‑grade epithelial ovarian cancer

Gong,Mi; Yan,Changsheng; Jiang,Yi; Meng,Huangyang; Feng,Mingming; Cheng,Wenjun

doi:10.3892/ol.2019.10736

Genome‑wide bioinformatics analysis reveals CTCFL is upregulated in high‑grade epithelial ovarian cancer

Authors:
- Mi Gong
- Changsheng Yan
- Yi Jiang
- Huangyang Meng
- Mingming Feng
- Wenjun Cheng
View Affiliations

Affiliations: Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Gastroenterology, Zhongshan Hospital Affiliated to Xiamen University, Xiamen, Fujian 361004, P.R. China
Published online on: August 8, 2019 https://doi.org/10.3892/ol.2019.10736
Pages: 4030-4039
Copyright: © Gong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy that threatens the health of females. Previous studies have demonstrated that the survival outcomes of patients with different EOC grades varied. Therefore, the EOC grade is considered to serve as a distinctive prognostic factor. To date, the evaluation of ovarian cancer grade relies on pathological examination and a quantitative index for diagnosis is lacking. Furthermore, the dysregulation of genes has been demonstrated to exert pivotal functions in the carcinogenesis of EOCs. Therefore, the identification of effective biomarkers associated with EOC grade is of importance for the development of therapeutic regimens, and also contributes to the prediction of EOC prognosis. Microarrays have been increasingly applied for the identification of potential molecular biomarkers for numerous diseases including EOC. In the present study, four public microarray datasets (GSE26193, GSE63885, GSE30161 and GSE9891) were analyzed. A total of 6,103 upregulated probes corresponding to 5,766 genes, and 4,004 downregulated probes corresponding to 3,707 genes were identified in the GSE26193, GSE63885 and GSE30161 datasets. ALK and LTK ligand 2 was the most downregulated gene associated with the tumor grade, while CCCTC‑binding factor like (CTCFL), EGF like domain multiple 6, radical S‑adenosyl methionine domain containing 2 and SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1 were the most upregulated genes associated with EOC grade. The GSE9891 dataset was added for further analysis. Only one probe (1552368_at) encoding for CTCFL was identified to be consistently upregulated in the four examined datasets. Immunohistochemical analysis was used to detect the expression of CTCFL between low‑ and high‑grade EOC tissues and revealed that the EOC grade was closely associated with CTCFL level. This was corroborated via the reverse transcription‑quantitative polymerase chain reaction. Taken together, the results of the present study suggested that CTCFL is upregulated in high‑grade epithelial ovarian cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Bast RC Jr, Hennessy B and Mills GB: The biology of ovarian cancer: New opportunities for translation. Nat Rev Cancer. 9:415–428. 2009. View Article : Google Scholar : PubMed/NCBI
3	Prat J: Ovarian carcinomas: Five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 460:237–249. 2012. View Article : Google Scholar : PubMed/NCBI
4	Yan C, Jiang Y, Wan Y, Zhang L, Liu J, Zhou S and Cheng W: Long noncoding RNA NBAT-1 suppresses tumorigenesis and predicts favorable prognosis in ovarian cancer. Onco Targets Ther. 10:1993–2002. 2017. View Article : Google Scholar : PubMed/NCBI
5	Jacobs AS, Schwartz MD, Valdimarsdottir H, Nusbaum RH, Hooker GW, DeMarco TA, Heinzmann JE, McKinnon W, McCormick SR, Davis C, et al: Patient and genetic counselor perceptions of in-person versus telephone genetic counseling for hereditary breast/ovarian cancer. Fam Cancer. 15:529–539. 2016. View Article : Google Scholar : PubMed/NCBI
6	Ganeshan D, Bhosale P, Wei W, Ramalingam P, Mudasiru- Dawodu E, Gershenson D, Sun C and Iyer R: Increase in post-therapy tumor calcification on CT scan is not an indicator of response to therapy in low-grade serous ovarian cancer. Abdom Radiol (NY). 41:1589–1595. 2016. View Article : Google Scholar : PubMed/NCBI
7	Hoppenot C, Eckert MA, Tienda SM and Lengyel E: Who are the long-term survivors of high grade serous ovarian cancer? Gynecol Oncol. 148:204–212. 2018. View Article : Google Scholar : PubMed/NCBI
8	Hacker KE, Uppal S and Johnston C: Principles of treatment for borderline, micropapillary serous, and low-grade ovarian cancer. J Natl Compr Canc Netw. 14:1175–1182. 2016. View Article : Google Scholar : PubMed/NCBI
9	Shih Ie M and Kurman RJ: Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am J Surg Pathol. 164:1511–1518. 2004. View Article : Google Scholar
10	Khalique L, Ayhan A, Weale ME, Jacobs IJ, Ramus SJ and Gayther SA: Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol. 211:286–295. 2007. View Article : Google Scholar : PubMed/NCBI
11	Chow YP, Alias H and Jamal R: Meta-analysis of gene expression in relapsed childhood B-acute lymphoblastic leukemia. BMC Cancer. 17:1202017. View Article : Google Scholar : PubMed/NCBI
12	Ding Y, Yang DZ, Zhai YN, Xue K, Xu F, Gu XY and Wang SM: Microarray expression profiling of long non-coding RNAs in epithelial ovarian cancer. Oncol Lett. 14:2523–2530. 2017. View Article : Google Scholar : PubMed/NCBI
13	Wang H, Fu Z, Dai C, Cao J, Liu X, Xu J, Lv M, Gu Y, Zhang J, Hua X, et al: LncRNAs expression profiling in normal ovary, benign ovarian cyst and malignant epithelial ovarian cancer. Sci Rep. 6:389832016. View Article : Google Scholar : PubMed/NCBI
14	Mateescu B, Batista L, Cardon M, Gruosso T, de Feraudy Y, Mariani O, Nicolas A, Meyniel JP, Cottu P, Sastre-Garau X and Mechta-Grigoriou F: miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med. 17:1627–1635. 2011. View Article : Google Scholar : PubMed/NCBI
15	Lisowska KM, Olbryt M, Dudaladava V, Pamula-Pilat J, Kujawa K, Grzybowska E, Jarzab M, Student S, Rzepecka IK, Jarzab B and Kupryjańczyk J: Gene expression analysis in ovarian cancer-faults and hints from DNA microarray study. Front Oncol. 4:62014. View Article : Google Scholar : PubMed/NCBI
16	Ferriss JS, Kim Y, Duska L, Birrer M, Levine DA, Moskaluk C, Theodorescu D and Lee JK: Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: Predicting platinum resistance. PLoS One. 7:e305502012. View Article : Google Scholar : PubMed/NCBI
17	Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, et al: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 14:5198–5208. 2008. View Article : Google Scholar : PubMed/NCBI
18	Taminau J, Meganck S, Lazar C, Steenhoff D, Coletta A, Molter C, Duque R, de Schaetzen V, Weiss Solis DY, Bersini H and Nowé A: Unlocking the potential of publicly available microarray data using inSilicoDb and inSilicoMerging R/Bioconductor packages. BMC Bioinformatics. 13:3352012. View Article : Google Scholar : PubMed/NCBI
19	Hong F, Breitling R, McEntee CW, Wittner BS, Nemhauser JL and Chory J: RankProd: A bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics. 22:2825–2827. 2006. View Article : Google Scholar : PubMed/NCBI
20	Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
21	Ito K and Murphy D: Application of ggplot2 to Pharmacometric Graphics. CPT Pharmacometrics Syst Pharmacol. 2:e792013. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Chan SK, Griffith OL, Tai IT and Jones SJ: Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer Epidemiol Biomarkers Prev. 17:543–552. 2008. View Article : Google Scholar : PubMed/NCBI
24	Botling J, Edlund K, Lohr M, Hellwig B, Holmberg L, Lambe M, Berglund A, Ekman S, Bergqvist M, Ponten F, et al: Biomarker discovery in non-small cell lung cancer: Integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res. 19:194–204. 2013. View Article : Google Scholar : PubMed/NCBI
25	Goonesekere NC, Wang X, Ludwig L and Guda C: A meta analysis of pancreatic microarray datasets yields new targets as cancer genes and biomarkers. PLoS One. 9:e930462014. View Article : Google Scholar : PubMed/NCBI
26	Singh G, Roy J, Rout P and Mallick B: Genome-wide profiling of the PIWI-interacting RNA-mRNA regulatory networks in epithelial ovarian cancers. PLoS One. 13:e01904852018. View Article : Google Scholar : PubMed/NCBI
27	Shi C and Zhang Z: Screening of potentially crucial genes and regulatory factors involved in epithelial ovarian cancer using microarray analysis. Oncol Lett. 14:725–732. 2017. View Article : Google Scholar : PubMed/NCBI
28	Januchowski R, Sterzynska K, Zawierucha P, Rucinski M, Swierczewska M, Partyka M, Bednarek-Rajewska K, Brazert M, Nowicki M, Zabel M, et al: Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell lines. Oncotarget. 8:49944–49958. 2017. View Article : Google Scholar : PubMed/NCBI
29	Wei S, Liu J, Shi Y, Zhang X, Yang Y and Song Q: Exploration of the sequential gene changes in epithelial ovarian cancer induced by carboplatin via microarray analysis. Mol Med Rep. 16:3155–3160. 2017. View Article : Google Scholar : PubMed/NCBI
30	He J, Huang Y, Liu Z, Zhao R, Liu Q, Wei L, Yu X, Li B and Qin Y: Hypomethylation of BORIS is a promising prognostic biomarker in hepatocellular carcinoma. Gene. 629:29–34. 2017. View Article : Google Scholar : PubMed/NCBI
31	Martin-Kleiner I: BORIS in human cancers-a review. Eur J Cancer. 48:929–935. 2012. View Article : Google Scholar : PubMed/NCBI
32	D'Arcy V, Pore N, Docquier F, Abdullaev ZK, Chernukhin I, Kita GX, Rai S, Smart M, Farrar D, Pack S, et al: BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br J Cancer. 98:571–579. 2008. View Article : Google Scholar : PubMed/NCBI
33	Kang Y, Hong JA, Chen GA, Nguyen DM and Schrump DS: Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells. Oncogene. 26:4394–4403. 2007. View Article : Google Scholar : PubMed/NCBI
34	Risinger JI, Chandramouli GV, Maxwell GL, Custer M, Pack S, Loukinov D, Aprelikova O, Litzi T, Schrump DS, Murphy SK, et al: Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression. Clin Cancer Res. 13:1713–1719. 2007. View Article : Google Scholar : PubMed/NCBI
35	Hoffmann MJ, Muller M, Engers R and Schulz WA: Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies. Biochem Pharmacol. 72:1577–1588. 2006. View Article : Google Scholar : PubMed/NCBI
36	Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K and Karpf AR: DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun. 7:212007.PubMed/NCBI
37	Link PA, Zhang W, Odunsi K and Karpf AR: BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer. Cancer Immun. 13:62013.PubMed/NCBI
38	Woloszynska-Read A, Zhang W, Yu J, Link PA, Mhawech-Fauceglia P, Collamat G, Akers SN, Ostler KR, Godley LA, Odunsi K and Karpf AR: Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: Association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res. 17:2170–2180. 2011. View Article : Google Scholar : PubMed/NCBI